NCT01233284 - Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma. | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2012

Conditions

Asthma

Interventions

DRUG

tiotropium bromide 2.5µg once daily

Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

DRUG

Tiotropium matching Placebo once daily

Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

DRUG

tiotropium bromide high dose once daily

Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

DRUG

tiotropium bromide 1.25µg once daily

IMP

Trial Locations (19)

205.380.43002 Boehringer Ingelheim Investigational Site, Hallein

205.380.43004 Boehringer Ingelheim Investigational Site, Linz

205.380.43005 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee

205.380.43001 Boehringer Ingelheim Investigational Site, Schlüsslberg

205.380.43003 Boehringer Ingelheim Investigational Site, Thalheim bei Wels

205.380.49006 Boehringer Ingelheim Investigational Site, Berlin

205.380.49010 Boehringer Ingelheim Investigational Site, Berlin

205.380.49003 Boehringer Ingelheim Investigational Site, Frankfurt

205.380.49004 Boehringer Ingelheim Investigational Site, Hamburg

205.380.49007 Boehringer Ingelheim Investigational Site, Hanover

205.380.49009 Boehringer Ingelheim Investigational Site, Mainz

205.380.49008 Boehringer Ingelheim Investigational Site, Schwerin

205.380.49001 Boehringer Ingelheim Investigational Site, Wiesbaden

205.380.49005 Boehringer Ingelheim Investigational Site, Wiesloch

205.380.38005 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk

205.380.38003 Boehringer Ingelheim Investigational Site, Kharkiv

205.380.38004 Boehringer Ingelheim Investigational Site, Kharkiv

205.380.38001 Boehringer Ingelheim Investigational Site, Kiev

205.380.38002 Boehringer Ingelheim Investigational Site, Kiev